hcv bi challeng revenue
acceler
lower pt old new
maintain ew rate believ
could miss us hcv guidanc think investor could
begin fear bi biosimilar newsflow risk
balanc acceler revenue growth
project conserv despit track record exceed
expect project revenu vs manag guidanc
flat sale due conserv us hcv project adj ep
bottom end guidanc rang estim
humira part drug price inquiri drug countri
long histori price increas said larg number
manufactur rais price significantli lead drug humira one
mani may face scrutini would expect emphas net
price increas grown slower rate list due rebat
compani deceler price increas recent year importantli see
potenti legisl bring list price drug unlik pass
revis humira estim appear achiev lower us humira
growth line guidanc think factor
increment rebat cours garner strong formulari
access launch risankizumab upadacitinib jak
reduc ex-u humira guidanc exhibit
out-year project note ex-u declin moder
price alreadi significantli re-set ceo gonzalez note
new biosimilar competit ex-u market yet face
competit larg occur rather
see risk hcv sale project declin us hcv
revenu vs mgmt forecast flat sale indic
expect unchang us sale base upon expect market share
gain offset declin total treat patient flattish price due channel
mix lower price commerci plan off-set lower mix va sale
forecast conserv gilead cover matthew
harrison initi regain share includ launch author gener
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
transit lower list price product could put pressur
hcv anticip
bi percept threat set rise unlik biosimilar
settl litig boehring ingelheim bi privat held continu
challeng us humira patent expect initi court trial
bioprocess intern quot bi spokesperson articl focu
bring cyltezo biosimilar humira us market
commit make avail us patient soon possibl certainli
note consensu current model amgen/allergan
first launch januari addit bi biosimilar
interchang trial voltaire-x primari complet date march
assum trial succe could facilit bi abil drive switch
exist us humira patient biosimilar pleas see biosimilar humira
challeng exhibit detail competit threat ex-u us
bullish abbvi pipelin dont see risk approv
upadacitinib mg note compel profil risankizumab il-
upadacitinib jak rel competit plu abil drive
rapid prefer formulari adopt leverag humira rebat expect
fda approv risankizumab upadacitinib although
investor express concern de-emphasize upadacitinib
mg dose would highlight phase select trial dose
-beyond -monotherapi -earli mg appear somewhat
less efficaci mg mg superior humira ra
select-compar test mg dose wherea approv
dose xeljanz mg lilli olumi mg shown
superior humira physician concern safeti new
drug potenti benign safeti label upadacitinib could help
garner adopt olumi black box warn thrombosi
said fda approv risankizumab upadacitinib surprisingli delay
could materi neg share
news revenue growth accel rate declin ex-u humira
moder new launch kick project total sale growth
acceler compani benefit
moder ex-u humira sale declin strong perform exist driver
 imbruvica venclexta new product ramp orilissa
risankizumab upadacitinib institut investor contact offic
full model
potenti could add new growth driver initi stock reaction difficult
predict although expect acquir small-mid size biotech
compani beyond enhanc growth prospect note
 environ highli competit like compet
target sever major pharma biotech compani transact
valuat could quit high
show biosimilar challeng humira us ex-u revenu forecast vs
pt base base case ep price-to-earnings multipl
peer mean due risk long-term humira declin
bull case ep
bull case ep
sale surpass expect drive ep project pipelin
develop deliv upsid surpris settl humira litig bi
us biosimilar entri later add new long-term growth driver
diversifi beyond humira help price-to-earnings
base case ep
base case ep
see balanc risk-reward expect strong ep growth posit
pipelin develop near-term balanc long-term humira biosimilar
threat includ risk us biosimilar interchang bi candid
bear case ep
bear case ep
earn forecast newsflow concern major franchis sale
disappoint caus ep expect pipelin candid
risankizumab and/or upadacitinib approv delay bi make progress
overcom humira patent investor discount us biosimilar entri
rather
equal-weight share
anticip solid ep growth
posit pipelin develop
growth near-medium term
balanc risk price-to-earnings contract long term
us biosimilar humira entri approach
like pursu extern
transact enhanc pipelin
surpris neg humira sale patent
financi result rel expect
humira imbruvica hcv sale
litig interchang trial readout
clinic trial result potenti btk
competitor imbruvica includ
acalabrutinib trial cll
extern busi develop
risk achiev price
upsid risk result
posit humira patent news value-
downsid risk result
disappoint problemat legal
project humira sale repres rapid first year
biosimilar eros impact us brand face date believ us
marketplac set drive adopt biosimilar version number one drug
countri assum humira face one biosimilar first half year
five competitor drive greater price eros volum uptak
histor preced would suggest
us biosimilar competit time six settl launch bi intend
litig patent current set face one biosimilar amgen/allergan
follow five biosimilar competitor june
exhibit detail said critic note risk biosimilar competit could
start earlier us boehring ingelheim publicli state intend
continu litig us patent launch earlier asid although
model extend beyond expect steeper rate annual sale
declin outer year
key swing factor annual us sale eros rate switch exist
humira patient expect certain payer employ physician dictat
prescrib kaiser permanent veteran administr forc
switch sinc competit among biosimilar like drive price
significantli expect privat sector plan use patient financi incent
encourag patient switch biosimilar
addit risk us humira includ earlier biosimilar entri interchang
boehring ingelheim seek humira patent thicket launch
believ earliest possibl launch would assum lower court
trial occur block patent invalid appel court
valid lower court rule favor bi separ bi conduct
biosimilar interchang studi call voltaire-x primari complet date
march assum trial succe could facilit bi abil drive switch
exist us humira patient biosimilar
exhibit humira biosimilar outlook us europ
launch us jan royalti abbvi
bi launch europ focu us litig
launch us june royalti abbvi
launch us sept royalti abbvi
launch us us juli pay royalti abbvi
launch us sept royalti eu launch
launch us royalti abbvi
enter phase
exhibit ms humira sale project consensu increas rate futur year
price
price
price
exhibit trade mean year histor mean
price data
price data
exhibit incom statement margin analysi valuat
sg sale
 sale
exhibit balanc sheet statement
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
